Holen Sie sich die Stockscreener-App
3.98
3.86%
-0.16
Handel nachbörslich:
4.03
0.05
+1.26%
Schlusskurs vom Vortag:
$4.14
Offen:
$4.1
24-Stunden-Volumen:
30,748
Relative Volume:
0.37
Marktkapitalisierung:
$36.85M
Einnahmen:
$4.01M
Nettoeinkommen (Verlust:
$-26.97M
KGV:
-1.3398
EPS:
-2.9707
Netto-Cashflow:
$-23.45M
1W Leistung:
+9.94%
1M Leistung:
-3.16%
6M Leistung:
-53.83%
1J Leistung:
-64.08%
1-Tages-Spanne:
$3.8901
$4.125
1-Wochen-Bereich:
$3.66
$4.41
52-Wochen-Spanne:
$3.51
$13.13
Cervomed Inc Stock (CRVO) Company Profile
Firmenname
Cervomed Inc
Sektor
Branche
Telefon
(617) 744-4400
Adresse
20 PARK PLAZA, BOSTON
Compare CRVO vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
3.98 | 38.33M | 4.01M | -26.97M | -23.45M | -2.9707 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-13 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-12-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-18 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-07-26 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-11-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cervomed Inc Aktie (CRVO) Neueste Nachrichten
CRVO PE Ratio & Valuation, Is CRVO Overvalued - Intellectia AI
CRVO.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
CRVO News & Events - Intellectia AI
CRVO Should I Buy - Intellectia AI
CervoMed sets 50mg dose for phase 3 dementia trial - Investing.com
CRVO Stock Price, Quote & Chart | CERVOMED INC (NASDAQ:CRVO) - ChartMill
CRVO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
CRVO Technical Analysis & Stock Price Forecast - Intellectia AI
Insider Buy: How do insiders feel about CervoMed IncPrice Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
CervoMed (CRVO)’s Q4 results feature advancements in its neflamapimod program for dementia Lewy bodies (DLB) - MSN
CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB) - Insider Monkey
CEO Change: Is CervoMed Inc stock overvalued or fairly priced2026 Technicals & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Top 5 Stocks Under $5 That Could Triple - insidermonkey.com
CervoMed Posts Investor Presentation Under Regulation FD Disclosure - TipRanks
CRVO: Phase III DLB trial launches this year, leveraging biomarker-driven selection and robust phase II data - TradingView
CervoMed (NASDAQ: CRVO) furnishes updated investor presentation via 8-K - Stock Titan
CervoMed Presents New Data Reinforcing Positive Effects of Tuvapimod in Dementia with Lewy Bodies Without Alzheimer’s Co-Pathology at AD/PD 2026 Conference - Minichart
CervoMed reports Phase 2b trial data for DLB treatment neflamapimod By Investing.com - in.investing.com
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results - TipRanks
[8-K] CervoMed Inc. Reports Material Event - Stock Titan
CervoMed (CRVO): Analyst Maintains Buy Rating with $31 Price Tar - GuruFocus
CervoMed (CRVO) Showcases Promising Trial Results for Neflamapim - GuruFocus
CervoMed Inc Announces New Data on Neflamapimod In Dementia With Lewy Bodies - marketscreener.com
CervoMed reports Phase 2b trial data for DLB treatment neflamapimod - Investing.com
CervoMed Inc. unveils new analyses linking better neflamapimod outcomes to reduced Alzheimer co-pathology - Traders Union
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology - The Manila Times
CervoMed Announces New Data at the AD/PD™ 2026 Scientific - GlobeNewswire
CRVO: Roth Capital Lowers Price Target, Maintains Buy Rating | C - GuruFocus
CervoMed (CRVO): Chardan Capital Raises Price Target to $21.00 | - GuruFocus
Market Trends: Is CervoMed Inc currently under institutional pressureDollar Strength & Smart Money Movement Tracker - baoquankhu1.vn
CervoMed Reports 2025 Results, Advances Neflamapimod Programs - TipRanks
CRVO: Phase 3 DLB trial planned for H2 2026, with cash runway limited to six months - TradingView
CervoMed (CRVO) widens 2025 loss as cash runway falls to six months - Stock Titan
Aug Macro: Is CervoMed Inc stock overvalued or fairly pricedWeekly Trading Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
H.C. Wainwright reiterates CervoMed stock rating on conference data By Investing.com - Investing.com India
H.C. Wainwright reiterates CervoMed stock rating on conference data - Investing.com
CervoMed Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Updates - tradingview.com
CervoMed Inc. Reports Positive Phase 2b Clinical Data and Plans for Phase 3 Trial in Dementia with Lewy Bodies - Quiver Quantitative
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates - ChartMill
CervoMed (CRVO) Maintains Current Analyst Ratings and Price Targ - GuruFocus
Manufacturing and Formulation Changes Threaten Cervomed’s Neflamapimod Development Timeline and Costs - The Globe and Mail
CervoMed Inc. (CRVO) reports Q4 loss, lags revenue estimates - MSN
CervoMed Inc. (CRVO) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates - sharewise.com
CervoMed Inc. Annual Report 2025: Strategy, Key Terms, and Forward-Looking Statements for Age-Related Brain Disorders - Minichart
CervoMed 10-K: $4.01M Grant Revenue; Net Loss $26.97M, $(2.98) EPS - TradingView
CRVO: Neflamapimod achieved robust, durable efficacy in DLB without AD co-pathology, advancing to Phase 3 - TradingView
CRVO: Net loss widened to $27.0 million in 2025; ongoing operations depend on new capital - TradingView
CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
CervoMed Inc expected to post a loss of 72 cents a shareEarnings Preview - TradingView
CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference - Sahm
Finanzdaten der Cervomed Inc-Aktie (CRVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):